Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your Number one Kind of Gems - 2Novo Nordisk cuts Wegovy price in South Africa for a second time
- 3Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- 4Strengthening through Wellness: Individual Preparation Achievement
- 5Best Amusement Park Bite: What Do You Very much want to Crunch On?
- What you need to know about desalination, a growing source of drinking water
- A Manual for Extravagant Vehicles Available in 2024
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- 25 of the world’s best sandwiches
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- The Fate of Rest: Patterns in Shrewd Beds
- 75% of US adults may meet criteria for obesity under new definition, study finds
- Family Holiday spots
